Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Macter International Limited

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000141 211 linked products · source seen 10 Aug 2026 View source ↗
DML 000641 37 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx248product presentations
G91generic molecules
DF11dosage-form groups
TA14therapeutic areas
PKR248current price records
REG201registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage94%
priced packs safely normalized per unit
Comparable-market coverage79%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixMacter International LimitedShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/macter-international-limitedGenerated 10 Aug 2026Anti-infectives111 · 45%Cardiovascular27 · 11%Hematology & thrombosis26 · 10%Respiratory & allergy16 · 6%Endocrine & metabolic15 · 6%Gastrointestinal & hepatology10 · 4%Oncology & immunology9 · 4%Other therapeutic areas34 · 14%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioMacter International LimitedDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/macter-international-limitedGenerated 10 Aug 2026248presentationsTablet113 · 46%Injection64 · 26%Suspension24 · 10%Capsule17 · 7%Inhalation11 · 4%Infusion6 · 2%Other forms13 · 5%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionMacter International LimitedCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/macter-international-limitedGenerated 10 Aug 2026197comparable productsBelow market median27 · 14%Near market median87 · 44%Above market median83 · 42%Company median price position+3.5%Lowest-price equivalents20Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsMacter International LimitedCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/macter-international-limitedGenerated 10 Aug 2026Nabiqasim Industries (Pvt) Ltd.,48 shared53% overlapM/s. Genix Pharma (Pvt) Ltd.46 shared51% overlapBio-Labs(Pvt) Ltd43 shared47% overlapNeutro Pharma (Pvt.) Ltd.,42 shared46% overlapBosch Pharmaceuticals (Pvt) Ltd.41 shared45% overlapMediate Pharmaceutical Pvt Ltd41 shared45% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives111 products · 45%
Cardiovascular27 products · 11%
Hematology & thrombosis26 products · 10%
Respiratory & allergy16 products · 6%
Endocrine & metabolic15 products · 6%
Gastrointestinal & hepatology10 products · 4%
Oncology & immunology9 products · 4%
Pain & musculoskeletal9 products · 4%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Penicillin antibacterials37 products · 15%
Third-generation cephalosporins16 products · 6%
Antivirals15 products · 6%
Antidiabetic medicines13 products · 5%
Anticoagulants13 products · 5%
Macrolide antibacterials9 products · 4%
Analgesics / NSAIDs9 products · 4%
Fluoroquinolone antibacterials8 products · 3%
Formulation footprint

Dosage forms

Tablet113 products
Injection64 products
Suspension24 products
Capsule17 products
Inhalation11 products
Infusion6 products
Syrup4 products
Vaccine4 products
Drops3 products
Cream1 products
Solution1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 Co-AmoxiAmoxicillin + clavulanic acid 15presentations 0.3 g total, 1.2 g total, 125 mg + 31.25 mg/5 mL, 250 mg + 125 mg · Injection, Suspension, Tablet #2 MaxilAmoxicillin 15presentations 125 mg/1.25 mL, 125 mg/5 mL, 250 mg, 250 mg/5 mL · Injection, Drops, Suspension #3 MazleroRivaroxaban 8presentations 10 mg, 15 mg, 20 mg · Tablet #4 Empozin-MEmpagliflozin + Metformin 6presentations 12.5 mg + 1000 mg, 12.5 mg + 500 mg, 5 mg + 1000 mg · Tablet #5 UltimaClarithromycin 6presentations 125 mg/5 mL, 250 mg, 500 mg · Drops, Suspension, Tablet #6 DeltoinPhenytoin sodium 5presentations 100 mg, 125 mg/5 mL, 250 mg/5 mL · Capsule, Suspension, Injection
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median2714% of comparable products
Near market median87within ±5% of median
Above market median8342% of comparable products
Lowest-price equivalents20ties included
Company median price position +3.5% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Paramac 500 mgParacetamol · Tablet · 1000's PKR 0.26/tablet-92.6% vs market median Macprofen 600 mgIbuprofen · Tablet · 24's PKR 2.54/tablet-59.7% vs market median Macprofen 600 mgIbuprofen · Tablet · 60's PKR 2.57/tablet-59.1% vs market median Tector 100 mcgMisoprostol · Tablet · 10 PKR 5.52/tablet-55.8% vs market median Tector 200 mcgMisoprostol · Tablet · 10's PKR 10.47/tablet-49.3% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 48shared generics M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 46shared generics Bio-Labs(Pvt) Ltd234 products · 82 generics 43shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 42shared generics Bosch Pharmaceuticals (Pvt) Ltd.250 products · 73 generics 41shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 41shared generics
Regulatory & price activity

Observed database signals

Registration numbers201
Price-history records291
Products with price history37
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date29 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

27 results
Intelligence filter: Therapeutic areaCardiovascular Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Amdrone Amiodarone 150 mg/3 mL Injection 1's 095144 PKR 87.37 PKR 87.37/vial/unit Near median
Amdrone Amiodarone 150 mg/3 mL Injection 6's 095144 PKR 485.37 PKR 80.90/vial/unit Near median
Dopacard Dopamine HCl 40 mg Injection 20's 021717 PKR 3,048.39 PKR 152.42/vial/unit Near median
Dopacard Dopamine HCl 40 mg Injection 5's 021717 PKR 778.21 PKR 155.64/vial/unit Near median
Hart Carvedilol 25 mg Tablet 10 037195 PKR 493.18 PKR 49.32/tablet 30% above median
Hart Carvedilol 6.25 mg Tablet 30 044034 PKR 394.55 PKR 13.15/tablet 23% above median
Hart Carvedilol 3.125 mg Tablet 10 044033 PKR 197.27 PKR 19.73/tablet 16% above median
Hart Carvedilol 12.5 mg Tablet 10 044035 PKR 147.96 PKR 14.80/tablet 8% above median
Lignomax AD Lidocaine + Adrenaline 20 mg/mL + 0.005 mg/mL Injection 10 x 10 ml 021728 PKR 298.39 PKR 2.98/mL Near median
Lignomax AD Lidocaine + Adrenaline 20 mg/mL + 0.005 mg/mL Injection 50 x 10 ml 021728 PKR 1,459.52 PKR 2.92/mL Near median
Tavist Atorvastatin 20 mg Tablet 10 044052 PKR 990.19 PKR 99.02/tablet 113% above median
Tavist Atorvastatin 40 mg Tablet 10 055986 PKR 726.14 PKR 72.61/tablet Near median
Tavist Atorvastatin 10 mg Tablet 10's 037056 PKR 462.09 PKR 46.21/tablet 68% above median
Tavist Plus Amlodipine + Atorvastatin 20 mg + 10 mg Tablet 10 057757 PKR 693.20 PKR 69.32/tablet 28% above median
Tavist Plus Amlodipine + Atorvastatin 20 mg + 5 mg Tablet 20 057756 PKR 1,216.14 PKR 60.81/tablet No comparator
Tavist Plus Amlodipine + Atorvastatin 10 mg + 5 mg Tablet 20 057755 PKR 802.66 PKR 40.13/tablet No comparator
Telam Telmisartan + Amlodipine 40 mg + 10 mg Tablet 14 079542 PKR 810.44 PKR 57.89/tablet 7% above median
Telam Telmisartan + Amlodipine 40 mg + 5 mg Tablet 14's 079540 PKR 735.80 PKR 52.56/tablet Near median
Telam Telmisartan + Amlodipine 80 mg + 5 mg Tablet 14's 079541 PKR 1,290.30 PKR 92.16/tablet 35% above median
Telam Telmisartan + Amlodipine 80 mg + 10 mg Tablet 14's 079543 PKR 1,226.33 PKR 87.60/tablet Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.